Nanobiotix S.A. (EPA: NANO)
Market Cap | 236.27M |
Revenue (ttm) | 36.21M |
Net Income (ttm) | -39.70M |
Shares Out | 47.40M |
EPS (ttm) | -1.08 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 67,046 |
Open | 4.932 |
Previous Close | 4.880 |
Day's Range | 4.750 - 5.020 |
52-Week Range | 3.816 - 9.430 |
Beta | 1.29 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Sep 13, 2024 |
About Nanobiotix
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater ... [Read more]
Financial Performance
In 2023, FGA's revenue was 402.01 million, an increase of 17.70% compared to the previous year's 341.55 million. Losses were -12.23 million, -32.32% less than in 2022.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/b/f/press4-2476631.jpg)
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appro...
![](https://cdn.snapi.dev/images/v1/j/m/press18-2457983.jpg)
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
PARIS and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based t...
![](https://cdn.snapi.dev/images/v1/d/a/conf9-2450588.jpg)
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based th...
![](https://cdn.snapi.dev/images/v1/c/o/conf7-2446397.jpg)
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approac...
![](https://cdn.snapi.dev/images/v1/8/a/press13-2442774.jpg)
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
PARIS and CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approac...
![](https://cdn.snapi.dev/images/v1/z/l/press4-2442434.jpg)
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
PARIS and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based t...
![](https://cdn.snapi.dev/images/v1/7/o/conf10-2433392.jpg)
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST
![](https://cdn.snapi.dev/images/v1/g/u/press7-2430743.jpg)
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based th...
![](https://cdn.snapi.dev/images/v1/d/n/press17-2389566.jpg)
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Prolonged survival in Study 102 re...
![](https://cdn.snapi.dev/images/v1/a/6/conf10-2376927.jpg)
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST
![](https://cdn.snapi.dev/images/v1/z/q/press11-2353087.jpg)
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
PARIS and CAMBRIDGE, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appr...
![](https://cdn.snapi.dev/images/v1/1/p/conf9-2311863.jpg)
Nanobiotix to Present at Upcoming Investor Conferences in March
PARIS and CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appro...
![](https://cdn.snapi.dev/images/v1/z/y/conf6-2254137.jpg)
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
PARIS and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approa...
![](https://cdn.snapi.dev/images/v1/3/m/press18-2249577.jpg)
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
PARIS and CAMBRIDGE, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based appro...
![](https://cdn.snapi.dev/images/v1/8/t/press12-2155562.jpg)
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR3 16.9 months median progression free survival (mPFS) and 23.1 mo...
![](https://cdn.snapi.dev/images/v1/c/i/conf19-2151050.jpg)
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET
![](https://cdn.snapi.dev/images/v1/h/v/press12-2145088.jpg)
NANOBIOTIX Announces Closing of Global Offering
PARIS and CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...
![](https://cdn.snapi.dev/images/v1/8/x/press10-2140892.jpg)
NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M
PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...
![](https://cdn.snapi.dev/images/v1/v/e/press12-2136601.jpg)
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...
![](https://cdn.snapi.dev/images/v1/a/p/press5-2134718.jpg)
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics...
![](https://cdn.snapi.dev/images/v1/4/2/press5-2114584.jpg)
NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile...
![](https://cdn.snapi.dev/images/v1/i/i/press6-2090379.jpg)
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Month
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society...
![](https://cdn.snapi.dev/images/v1/f/g/press18-2084391.jpg)
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST
![](https://cdn.snapi.dev/images/v1/p/e/press14-2082761.jpg)
NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research
![](https://cdn.snapi.dev/images/v1/h/v/press7-2078840.jpg)
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Upfront payment and first equity t...